73956
document
Propranolol in acute myocardial infarction : the MILIS experience . The results of the propranolol limb of the Multicenter Investigation of the Limitation of Infarct Size are reviewed . A total of 269 patients , who presented with symptoms and electrocardiographic signs suggesting acute myocardial infarction were randomized to acute intravenous and subsequent oral therapy with propranolol ( n = 134 ) or placebo ( n = 135 ) . Eligibility for acute beta-blocker therapy was determined on the basis of readily available , noninvasive tests . Therapy was started at an average time of 8.5 hours after onset of symptoms . The full induction dose of intravenous propranolol ( 0.1 mg/kg ) was tolerated by 90 % of treated patients , and oral maintenance therapy was being continued in 82 % of treated patients on the second hospital day . There was a significant reduction in heart rate throughout maintenance therapy with propranolol , which continued through the tenth hospital day . There was no significant difference in the incidence of congestive heart failure between propranolol- and placebo-treated groups . There was also no significant difference between the 2 groups in infarct size estimated by measurement of serum CK-MB , planimetry of infarct area on technetium pyrophosphate myocardial scintigrams or R-wave measurements in patients with transmural anterior and inferior infarcts . There was no significant difference in mortality between the 2 groups during an average of 36 months ' follow-up . Although propranolol can be administered safely to patients with acute myocardial infarction who are selected on the basis of simple clinical criteria , there is no evidence of reduction of infarct size when beta blockade is begun 8.5 hours after the onset of symptoms .
73957
Intervention_Pharmacological
Propranolol
73958
Intervention_Pharmacological
propranolol
73959
Intervention_Pharmacological
propranolol
73960
Intervention_Control
placebo
73961
Intervention_Pharmacological
propranolol
73962
Intervention_Pharmacological
propranolol-
73963
Intervention_Control
placebo-treated
73964
Intervention_Pharmacological
propranolol
73965
Outcome_Physical
heart rate
73966
Outcome_Physical
incidence of congestive heart failure
73967
Outcome_Physical
infarct size
73968
Outcome_Physical
serum CK-MB , planimetry of infarct area on technetium pyrophosphate myocardial scintigrams or R-wave measurements
73969
Outcome_Mortality
mortality
73970
Outcome_Physical
infarct size
73971
Participant_Condition
acute myocardial infarction :
73972
Participant_Sample-size
269
73973
Participant_Condition
symptoms and electrocardiographic signs suggesting acute myocardial infarction
73974
Participant_Condition
acute myocardial infarction